Cantargia’s project pipeline
Nadunolimab (CAN04)
- Cantargia’s most advanced project
- Investigated in multiple clinical trials for treatment of various forms of cancer
- Ongoing clinical studies focus on various types of combination therapies
CAN10
- Designed for treatment of autoimmune and inflammatory diseases
- Currently in late-stage preclinical phase
- Phase I clinical trial expected to start in the first half of 2023
CANxx
- IL1RAP-based antibody platform
- Allows Cantargia to develop novel IL1RAP-binding antibodies with unique modes of action
